SYSTEM FOR ACTIVATING HUMAN APOBEC/AID CYTIDINE DEAMINASES AND/OR HUMAN URACIL-DNA-GLYCOSYLASE UNG AND ITS USE FOR ELIMINATING CCC DNA OF HEPATITIS B VIRUS FROM HUMAN CELLS, PARTICULARLY HEPATOCYTES Russian patent published in 2019 - IPC A61K31/7088 A61K38/00 A61P31/20 

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, namely to biotechnology and genetic engineering, and can be used to produce a system for APOBEC/AID-mediated and/or UNG-mediated DNA degradation of hepatitis B virus. A system for APOBEC/AID-mediated and/or UNG-mediated DNA degradation of hepatitis B virus, includes fused protein dCas9-X, where dCas9 is a mutant Cas9 protein lacking endonuclease activity, and X is an effector protein selected from a human acetyl transferase cor-protein p300 or VP48, VP64, VP160, VP192 and p65HSF1, and (II) RNA-conductors specific to regulatory elements of one or more human APOBEC/AID cytidine deaminases genes and/or human uracil-DNA glycosylase gene, wherein said RNA-conductors are used to attract dCas9 to said regulatory elements. Group of inventions also relates to use of the declared system for APOBEC/AID-mediated and/or UNG-mediated DNA degradation of hepatitis B virus.

EFFECT: using this group of invention provides for the activation of APOBEC/AID cytidine deaminase genes and/or human uracil-DNA glycosylase with provision of deamination of cytosine bases of viral DNA with subsequent excision of formed uracil residues, degradation of viral DNA and its elimination from human cells, particularly hepatocyte.

5 cl, 3 tbl, 8 dwg